乙肝治疗性疫苗的研制与临床应用  

Development of Therapeutic Vaccines Against Hepatitis B and Clinical Application

作　　者：李杨[1,2] 王赛锋[2] 王亚男[1] 孟颂东[2] 

机构地区：[1]四川师范大学生命科学学院,成都610068 [2]中国科学院微生物研究所病原微生物与分子免疫中心院重点实验室,北京100101

出　　处：《生物技术通报》2010年第4期33-37,共5页Biotechnology Bulletin

基　　金：国家"863"项目(2006AA02A241)

摘　　要：尽管乙肝预防性疫苗非常有效,我国仍有约9300万乙肝病毒(HBV)携带者。抗病毒治疗疗效有限,患者长期使用容易产生耐药性。因此,研制乙肝治疗性疫苗可补充甚至替代目前的抗病毒治疗。T细胞免疫对于乙肝病毒的控制和清除至关重要,目前已经设计出蛋白疫苗、表位多肽疫苗以及DNA或病毒载体疫苗通过临床试验检验其疗效。将就研制乙肝治疗性疫苗这一日益活跃的领域加以概述,着重评价疫苗的细胞免疫应答和临床疗效。While efficient preventive vaccines are available for HBV,there are still about 93 million people infected with HBV in China.The present antiviral therapies for chronically infected patients are yet poorly efficient,and drug-resistant HBV mutants frequently arise.Thus,therapeutic vaccines are actively being developed to complement or even replace standard antiviral treatments.T cells are believed to play key roles for virus control and clearance.Recombinant protein-,epitope,DNA or viral vector-based vaccines have been engineered and tested in clinical trials.This article reviews advances of therapeutic hepatitis B vaccine development which is now an increasingly active field,with a particular focus on the cellular immunoresponse and clinical efficacy.

关 键 词：乙肝 乙肝病毒 治疗性疫苗 CTL 

分 类 号：R392[医药卫生—免疫学]